

Amanda Heslegrave

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5884611/publications.pdf>

Version: 2024-02-01

77
papers

3,012
citations

136950

32
h-index

182427

51
g-index

85
all docs

85
docs citations

85
times ranked

5185
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 3.	10.8	236
2	C9orf72-binding small molecules ameliorate C9orf72-associated FTD / ALS pathology <i>in vitro</i> and <i>in vivo</i> . <i>EMBO Molecular Medicine</i> , 2018, 10, 22-31.	6.9	178
3	The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	170
4	Molecular biomarkers of Alzheimer's disease: progress and prospects. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	2.4	163
5	Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	134
6	Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. <i>Molecular Neurodegeneration</i> , 2015, 10, 64.	10.8	121
7	Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. <i>Molecular Psychiatry</i> , 2020, 25, 2919-2931.	7.9	99
8	Cerebrospinal fluid tau, A β , and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. <i>Alzheimer's and Dementia</i> , 2018, 14, 1159-1170.	0.8	96
9	Activation of AMP-activated Protein Kinase by Vascular Endothelial Growth Factor Mediates Endothelial Angiogenesis Independently of Nitric-oxide Synthase. <i>Journal of Biological Chemistry</i> , 2010, 285, 10638-10652.	3.4	74
10	Axonal marker neurofilament light predicts long-term outcomes and progressive neurodegeneration after traumatic brain injury. <i>Science Translational Medicine</i> , 2021, 13, eabg9922.	12.4	74
11	Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1587-1595.	3.0	73
12	Exercise as a potential modulator of inflammation in patients with Alzheimer's disease measured in cerebrospinal fluid and plasma. <i>Experimental Gerontology</i> , 2019, 121, 91-98.	2.8	72
13	Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 19.	6.2	65
14	The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy – A prospective, pilot observational study. <i>PLoS ONE</i> , 2019, 14, e0211184.	2.5	64
15	Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	64
16	Sense and antisense RNA are not toxic in Drosophila models of C9orf72-associated ALS/FTD. <i>Acta Neuropathologica</i> , 2018, 135, 445-457.	7.7	59
17	In vivo detection of cerebral tau pathology in long-term survivors of traumatic brain injury. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	56
18	Nitric oxide-dependent damage to neuronal mitochondria involves the NMDA receptor. <i>European Journal of Neuroscience</i> , 2002, 15, 458-464.	2.6	54

#	ARTICLE	IF	CITATIONS
19	Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 113.	6.2	54
20	<i>PDXK</i> mutations cause polyneuropathy responsive to pyridoxal 5-phosphate supplementation. <i>Annals of Neurology</i> , 2019, 86, 225-240.	5.3	54
21	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2021, 290, 583-601.	6.0	54
22	OUP accepted manuscript. <i>Brain</i> , 2021, 144, 434-449.	7.6	54
23	CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e512.	6.0	50
24	Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 448-451.	2.4	49
25	Deletion of <i>Lkb1</i> in Pro-Opiomelanocortin Neurons Impairs Peripheral Glucose Homeostasis in Mice. <i>Diabetes</i> , 2011, 60, 735-745.	0.6	48
26	A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology. <i>Translational Psychiatry</i> , 2016, 6, e952-e952.	4.8	46
27	Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 314-319.	3.1	46
28	Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome. <i>Journal of Neuroinflammation</i> , 2020, 17, 86.	7.2	44
29	Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 39.	6.2	43
30	Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 79.	6.2	43
31	Plasma tau is increased in frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 804-807.	1.9	41
32	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1189-1201.	2.6	38
33	Combined tissue and fluid proteomics with Tandem Mass Tags to identify low-abundance protein biomarkers of disease in peripheral body fluid: An Alzheimer's Disease case study. <i>Rapid Communications in Mass Spectrometry</i> , 2017, 31, 153-159.	1.5	35
34	Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 13-22.	3.8	29
35	Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X. <i>Human Molecular Genetics</i> , 2019, 28, 3528-3542.	2.9	29
36	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. <i>NeuroImage: Clinical</i> , 2019, 24, 102077.	2.7	27

#	ARTICLE	IF	CITATIONS
37	Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 56-76.	1.5	27
38	Cerebrospinal fluid neurogranin and TREM2 in Huntingtonâ€™s disease. <i>Scientific Reports</i> , 2018, 8, 4260.	3.3	25
39	Tau and neurofilament lightâ€œchain as fluid biomarkers in spinocerebellar ataxia type 3. <i>European Journal of Neurology</i> , 2022, 29, 2439-2452.	3.3	25
40	Congenital Hyperinsulinism due to mutations in HNF4A and HADH. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2010, 11, 185-191.	5.7	21
41	Amyloid Î² peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 311-321.	2.4	21
42	Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 94.	6.2	20
43	A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	18
44	A longitudinal and crossâ€œsectional study of plasma neurofilament light chain concentration in <sc>Charcotâ€œMarieâ€œTooth</sc> disease. <i>Journal of the Peripheral Nervous System</i> , 2022, 27, 50-57.	3.1	16
45	A multi-center study of neurofilament assay reliability and inter-laboratory variability. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 452-458.	1.7	15
46	Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease. <i>Movement Disorders</i> , 2021, 36, 503-508.	3.9	15
47	Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	14
48	Breaking the cycle. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e562.	6.0	12
49	Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntingtonâ€™s disease. <i>Scientific Reports</i> , 2021, 11, 3481.	3.3	12
50	Plasma neurofilament light chain protein as a predictor of days in delirium and deep sedation, mortality and length of stay in critically ill patients. <i>EBioMedicine</i> , 2022, 80, 104043.	6.1	12
51	Multicentre longitudinal study of fluid and neuroimaging BIOMarkers of AXonal injury after traumatic brain injury: the BIO-AX-TBI study protocol. <i>BMJ Open</i> , 2020, 10, e042093.	1.9	11
52	Inflammatory markers of CHMP2B-mediated frontotemporal dementia. <i>Journal of Neuroimmunology</i> , 2018, 324, 136-142.	2.3	10
53	Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression. <i>Journal of Affective Disorders</i> , 2021, 286, 275-281.	4.1	9
54	Combining biomarkers for prognostic modelling of Parkinsonâ€™s disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 707-715.	1.9	9

#	ARTICLE	IF	CITATIONS
55	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. <i>PLoS ONE</i> , 2022, 17, e0267298.	2.5	9
56	Neurofilament Light in CSF and Plasma Is a Marker of Neuronal Damage in HTLV-1-Associated Myelopathy and Correlates With Neuroinflammation. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	8
57	Interlaboratory validation of cerebrospinal fluid β -synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 461-470.	2.4	7
58	Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. <i>European Journal of Neurology</i> , 2022, 29, 3347-3357.	3.3	7
59	Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid- β Concentration. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 885-891.	2.6	6
60	Neurofilament light plasma concentration positively associates with age and negatively associates with weight and height in the dog. <i>Neuroscience Letters</i> , 2021, 744, 135593.	2.1	6
61	A population-based study of head injury, cognitive function and pathological markers. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 842-856.	3.7	5
62	Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis. <i>Journal of Neurology</i> , 2022, 269, 1470-1475.	3.6	5
63	Association of CSF sTREM2, a marker of microglia activation, with cholinergic basal forebrain volume in major depressive disorder. <i>Journal of Affective Disorders</i> , 2021, 293, 429-434.	4.1	5
64	Serum neurofilament light concentration does not increase following exposure to low velocity football heading. <i>Science and Medicine in Football</i> , 2021, 5, 1-7.	2.0	4
65	Cerebrospinal fluid neurofilament light levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment. <i>F1000Research</i> , 2021, 10, 614.	1.6	4
66	Genetic Variants and Related Biomarkers in Sporadic Alzheimer's Disease. <i>Current Genetic Medicine Reports</i> , 2015, 3, 19-25.	1.9	3
67	Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment. <i>F1000Research</i> , 0, 10, 614.	1.6	2
68	Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, , 1-12.	2.8	2
69	Haem oxygenase/nitric oxide synthase interaction: a role in neurodegeneration?. <i>Biochemical Society Transactions</i> , 2002, 30, A84-A84.	3.4	0
70	P2-105: IDENTIFYING MARKERS OF MICROGLIA ACTIVATION IN CSF FROM PATIENTS WITH ALZHEIMER'S DISEASE USING A NOVEL MASS SPECTROMETRY APPROACH. , 2014, 10, P509-P509.		0
71	P1-188: MODELLING AMYLOID BETA PROFILES IN IPSC-DERIVED CORTICAL NEURONS OF MULTIPLE FAMILIAL ALZHEIMER'S DISEASE GENOTYPES, INCLUDING A CASE STUDY OF SAME DONOR CULTURE MEDIA, CSF AND BRAIN TISSUE. <i>Alzheimer's and Dementia</i> , 2018, 14, P350.	0.8	0
72	O2-04-04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P623.	0.8	0

#	ARTICLE	IF	CITATIONS
73	P1â€026: CEREBROSPINAL FLUID TAU, AÎ², AND STREM2 IN FORMER NATIONAL FOOTBALL LEAGUE PLAYERS: MODELING THE RELATIONSHIP BETWEEN REPETITIVE HEAD IMPACTS, MICROGLIAL ACTIVATION, AND NEURODEGENERATION. <i>Alzheimer's and Dementia</i> , 2018, 14, P275.	0.8	0
74	D09â€...Parallel evaluation of mutant huntingtin and neurofilament light as biomarkers for huntingtonâ€™s disease: the hd-csf study. , 2018, , .		0
75	O3â€09â€03: SERUM NEUROFILAMENT LIGHT LEVELS CORRELATE WITH SEVERITY MEASURES AND NEURODEGENERATION MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1037.	0.8	0
76	F05â€...Biological and clinical characteristics of gene carriers far from predicted onset in the hd-yas study: a cross-sectional analysis. , 2021, , .		0
77	308â€...Increased acute exposure to soccer ball heading shows no response from biochemical markers for axonal injury. , 2021, , .		0